Drug Approval | November 16, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Diversifying its portfolio to include late-phase antiviral agent
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
The observations are procedural in nature and will be responded to within the stipulated time
Subscribe To Our Newsletter & Stay Updated
